1198185-81-7

Basic information

• Product Name: (2S)-2-AMino-2-cyclopropylethan-1-ol HCl
• Synonyms: (2S)-2-AMino-2-cyclopropylethan-1-ol HCl;(2S)-2-AMINO-2-CYCLOPROPYLETHAN-1-OL;(2S)-2-Amino-2-cyclopropylethan-1-olhydrochloride;(S)-2-amino-2-cyclopropylethanol
• CAS NO: 1198185-81-7
• Molecular Formula: C5H12ClNO
• Molecular Weight: 137.60788
• Mol File: 1198185-81-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2S)-2-AMino-2-cyclopropylethan-1-ol HCl(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-2-AMino-2-cyclopropylethan-1-ol HCl(1198185-81-7)
• EPA Substance Registry System: (2S)-2-AMino-2-cyclopropylethan-1-ol HCl(1198185-81-7)

Safety Data

• Hazardous Substances Data: 1198185-81-7(Hazardous Substances Data)

Usage

General Description

"(2S)-2-Amino-2-cyclopropylethan-1-ol HCl" is a chemical compound with the molecular formula C5H11NO.HCl. It is a chiral compound, meaning that it has two enantiomers that are mirror images of each other. (2S)-2-AMino-2-cyclopropylethan-1-ol HCl is an amino alcohol, which means it contains both an amino group (-NH2) and a hydroxyl group (-OH). The cyclopropyl group in the molecule adds to its structural complexity and may influence its chemical and biological properties. (2S)-2-AMino-2-cyclopropylethan-1-ol HCl may have potential pharmaceutical applications due to its unique structure and properties, such as being used as a building block in organic synthesis or as a potential drug candidate.

Upstream product

• 776315-65-2 2-benzylamino-2-cyclopropylethanol 
• 49606-99-7 (S)-2-amino-2-cyclopropylacetic acid 
• 1623432-63-2 (2S)-2-amino-2-cyclopropylethan-1-ol hydrochloride 

Downstream Products

• 1623432-68-7 methyl 4-(2-((3R,5R,6S)-1-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-6-(4-chloro-3-fluorophenyl)-5-(3-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)acetamido)-2-methoxybenzoate 
• 1623432-51-8 4-(2-((3R,5R,6S)-1-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-6-(4-chloro-3-fluorophenyl)-5-(3-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)acetamido)-2-methoxybenzoic acid 
• 1623432-64-3 (3S,5R,6S)-3-allyl-6-(4-chloro-3-fluorophenyl)-5-(3-chlorophenyl)-1-((S)-1-cyclopropyl-2-hydroxyethyl)-3-methylpiperidin-2-one 
• 1623432-66-5 (3S,5S,6R,8S)-8-allyl-6-(3-chloro-2-fluorophenyl)-5-(4-chlorophenyl )-3-cyclopropyl-8-methyl-2 ,3, 5,6 ,7,8-hexahydrooxazolo[3,2-a]pyridin-4-ium 4-methylbenzenesulfonate 
• 1623432-67-6 (3S,5R,6S)-3-allyl-1-((S)-2-(tert-butylthio)-1-cyclopropylethyl)-6-(4-chloro-3-fluorophenyl)-5-(3-chlorophenyl)-3-methylpiperidin-2-one 
• 1584731-94-1 2-((3R,5R,6S)-1-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-6-(4-chloro-3-fluorophenyl)-5-(3-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 
• 1623432-52-9 (2S)-2-((2R,3R)-2-(3-chlorophenyl)-3-(4-chlorophenyl)-3-hydroxypropyl)-N-((S)-1-cyclopropyl-2-hydroxyethyl)-2-methylpent-4-enamide 
• 1640128-71-7 (3S,5S,6R,8S)-8-allyl-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-cyclopropyl-8-methyl-2,3,5,6,7,8-hexahydrooxazolo[3,2-a]pyridin-4-ium 4-methylbenzenesulfonate 
• 1352066-57-9 2-((3R,5R,6S)-1-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 
• 1584731-91-8 2-((3R,5R,6S)-1-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)acetic acid chloride 
• 1584731-41-8 2-((3R,5R,6S)-1-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)acetamide 
• 1623432-50-7 2-((3R,5R,6S)-1-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)-N-phenylacetamide 
• 1640128-68-2 (2S)-2-((2R,3R)-3-(4-chloro-3-fluorophenyl)-2-(3-chlorophenyl)-3-hydroxypropyl)-N-((S)-1-cyclopropyl-2-hydroxyethyl)-2-methylpent-4-enamide 
• 1428768-56-2 C₁₇H₂₅NO₃ 

Relevant articles and documents

2-AMINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF

The disclosure provides an aminopyrimidine derivative for preventing and treating diseases related to IDH mutation, a preparation method and use thereof. Specifically, the disclosure provides a compound of Formula I, a stereoisomer, racemate thereof, or pharmaceutically acceptable salt thereof. The compound of the general Formula I has isocitrate dehydrogenase 1 (IDH1) inhibitory activity and can treat cancer induced by IDH1 mutation.

Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction

Structure-based rational design and extensive structure-activity relationship studies led to the discovery of AMG 232 (1), a potent piperidinone inhibitor of the MDM2-p53 association, which is currently being evaluated in human clinical trials for the treatment of cancer. Further modifications of 1, including replacing the carboxylic acid with a 4-amidobenzoic acid, afforded AM-7209 (25), featuring improved potency (KD from ITC competition was 38 pM, SJSA-1 EdU IC50 = 1.6 nM), remarkable pharmacokinetic properties, and in vivo antitumor activity in both the SJSA-1 osteosarcoma xenograft model (ED50 = 2.6 mg/kg QD) and the HCT-116 colorectal carcinoma xenograft model (ED50 = 10 mg/kg QD). In addition, 25 possesses distinct mechanisms of elimination compared to 1.

Substituted Pteridines

The invention relates to new pteridines which are suitable for treating respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system and cancers. This invention also relates to pharmaceutical compositions containing these compounds.